Bladder cancer epidemiology and genetic susceptibility

Journal of Biomedical Research

Volumn 27, Issue 3, 2013, Pages 170-178

  Chu, Haiyan ^a,b   Wang, Meilin ^a,b   Zhang, Zhengdong ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

Author keywords

Bladder cancer; Genetic susceptibility; Molecular epidemiology; Risk factors

Indexed keywords

AMINOPHENOL DERIVATIVE; AROMATIC AMINE; CARCINOGEN; HYDROGEN PEROXIDE; MICRORNA; PARACETAMOL; PHENACETIN; POLYCYCLIC AROMATIC HYDROCARBON;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; COLORECTAL CANCER; DNA REPAIR; DRINKING BEHAVIOR; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITARY COLORECTAL CANCER; HEREDITY; HUMAN; MOLECULAR EPIDEMIOLOGY; OCCUPATIONAL EXPOSURE; ONCOGENE; PASSIVE SMOKING; SMOKING;

EID: 84884139711     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20130026     Document Type: Article

References (108)

1. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol 2010; 40 (S1): i57-64.
2. Wu X, Ros MM, Gu J and Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008; 102: 1207-15.
3. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 1989; 44: 622-8.
4. Kogevinas M, t Mannetje A, Cordier S, Ranft U, Gonzalez CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14: 907-14.
5. Johansson S, Wahlqvist L Tumours of urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. Acta Pathol Microbiol Scand A 1977; 85: 768-74.
6. Donato F, Boffetta P, Fazioli R, Aulenti V, Gelatti U and Porru S Bladder cancer, tobacco smoking, coffee and alcohol drinking in Brescia, northern Italy. Eur J Epidemiol 1997; 13: 795-800.
7. Kawaoka T, Miyagawa Y, Tsujihata M, Kamoto A, Nonomura N, Okuyama A. Two cases of bladder cancer with hereditary nonpolyposis colorectal cancer. Hinyokika Kiyo 2011; 57: 319-21.
8. Plna K and Hemminki K Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001; 166: 2129-33.
9. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001; 10: 1249-52.
10. Wang M, Wang M, Yuan L, Wu D, Zhang Z, Yin C, et al. A novel XPF-357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene 2010; 29: 1920-8.
11. Wang M, Zhang Z, Tian Y, Shao J and Zhang Z A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 2009; 15: 2567-72.
12. Wang M, Chu H, Li P, Yuan L, Fu G, Ma L, et al. Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res 2012; 72: 6173-82.
13. Horikawa Y, Gu J and Wu X. Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. Curr Opin Urol 2008; 18: 493-8.
14. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40: 1307-12.
15. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42: 415-9.
16. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, et al. Genetic variation in the prostate stem cell anti-gen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009; 41: 991-5.
17. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41: 221-7.
18. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010; 42: 978-84.
19. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000; 89: 630-9.
20. Wilhelm-Benartzi CS, Christensen BC, Koestler DC, Andres Houseman E, Schned AR, Karagas MR, et al. Association of secondhand smoke exposures with DNA methylation in bladder carcinomas. Cancer Causes Control 2011; 22: 1205-13.
21. Alberg AJ, Kouzis A, Genkinger JM, Gallicchio L, Burke AE, Hoffman SC, et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol 2007; 165: 660-6.
22. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer 2005; 92: 426-9.
23. Mills PK, Beeson WL, Phillips RL, Fraser GE. Bladder cancer in a low risk population: results from the Adventist Health Study. Am J Epidemiol 1991; 133: 230-9.
24. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol 1993; 3: 211-6.
25. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. Cancer Causes Control 2004; 15: 341-8.
26. Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Arch Environ Health 1991; 46: 6-15.
27. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34.
28. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191-308.
29. Sorahan T, Hamilton L, Wallace DM, Bathers S, Gar-diner K, Harrington JM. Occupational urothelial tumours: a regional case-control study. Br J Urol 1998; 82: 25-32.
30. Vineis P, Pirastu R. Aromatic amines and cancer. Can-cer Causes Control 1997; 8: 346-55.
31. Brown T, Slack R, Rushton L. Occupational cancer in Britain. Urinary tract cancers: bladder and kidney. Br J Cancer 2012; 107 (S1) 1: 76-84.
32. Czene K, Tiikkaja S, Hemminki K. Cancer risks in hair-dressers: assessment of carcinogenicity of hair dyes and gels. Int J Cancer 2003; 105: 108-12.
33. Handa SP, Tewari HD. Urinary tract carcinoma in patients with analgesic nephropathy. Nephron 1981; 28: 62-4.
34. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313: 292-5.
35. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 2001; 12: 690-4.
36. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43: 342-9.
37. Holubek WJ, Kalman S, Hoffman RS. Acetaminopheninduced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2006; 43: 880; author reply: 882.
38. Bernal W. Changing patterns of causation, the use of transplantation in the United Kingdom. Semin Liver Dis 2003; 23: 227-37.
39. Peniston JH. A review of pharmacotherapy for chronic low back pain with considerations for sports medicine. Phys Sportsmed 2013; 40: 21-32.
40. Chou R, Qaseem A, Snow V, Casey D, Cross JT, Jr., Shekelle P, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147: 478-91.
41. Heuch I, Hagen K, Heuch I, Nygaard O, Zwart JA. The impact of body mass index on the prevalence of low back pain: the HUNT study. Spine (Phila Pa 1976) 2010; 35: 764-8.
42. Boffetta P, Hashibe M. Alcohol, cancer. Lancet Oncol 2006; 7: 149-56.
43. Lu CM, Lan SJ, Lee YH, Huang JK, Huang CH, Hsieh CC. Tea consumption: fluid intake and bladder cancer risk in Southern Taiwan. Urology 1999; 54: 823-8.
44. Sala M, Cordier S, Chang-Claude J, Donato F, Escolar-Pujolar A, Fernandez F, et al. Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 2000; 11: 925-31.
45. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol 2003; 14: 973-1005.
46. Jiang X, Castelao JE, Groshen S, Cortessis VK, Ross RK, Conti DV, et al. Alcohol consumption and risk of bladder cancer in Los Angeles County. Int J Cancer 2007; 121: 839-45.
47. Pelucchi C, Negri E, Franceschi S, Talamini R, La Vec-Chia C. Alcohol drinking and bladder cancer. J Clin Epidemiol 2002; 55: 637-41.
48. Zeegers MP, Volovics A, Dorant E, Goldbohm RA, van den Brandt PA. Alcohol consumption and bladder cancer risk: results from The Netherlands Cohort Study. Am J Epidemiol 2001; 153: 38-41.
49. Djousse L, Schatzkin A, Chibnik LB, D'Agostino RB, Kreger BE, Ellison RC. Alcohol consumption and the risk of bladder cancer in the Framingham Heart Study. J Natl Cancer Inst 2004; 96: 1397-400.
50. La Vecchia C, Negri E, Decarli A, D'Avanzo B, Liberati C, Franceschi S. Dietary factors in the risk of bladder cancer. Nutr Cancer 1989; 12: 93-101.
51. Ciccone G, Vineis P. Coffee drinking, bladder cancer. Cancer Lett 1988; 41: 45-52.
52. D'Avanzo B, La Vecchia C, Franceschi S, Negri E, Talamini R, Buttino I. Coffee consumption and bladder cancer risk. Eur J Cancer 1992; 28A: 1480-4.
53. Daugherty SE, Laceyjr JV, Pfeiffer RM, Park Y, Hoover RN, Silverman DT. Reproductive factors and menopau-sal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2013 Jan 15. 10.1002/ijc.28022.[Epub ahead of print].
54. Choi Y, Giovannucci E, Lee JE. Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis. Br J Nutr 2012; 108: 1934-47.
55. Ros MM, Bueno-de-Mesquita HB, Kampman E, Aben KK, Buchner FL, Jansen EH, et al. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2012; 96: 902-10.
56. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. Cancer 2006; 107: 705-11.
57. Aben KK, Witjes JA, Schoenberg MP, De Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002; 98: 274-8.
58. Randi G, Pelucchi C, Negri E, Talamini R, Galeone C, Franceschi S, et al. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer 2007; 121: 2748-52.
59. Murta-Nascimento C, Silverman DT, Kogevinas M, Garcia-Closas M, Rothman N, Tardon A, et al. Risk of bladder cancer associated with family history of cancer: do lowpenetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007; 16: 1595-600.
60. Ilic M, Stojadinovic M, Milosavljevic Z. Familial aggregation of bladder cancer. Vojnosanit Pregl 2011; 68: 447-51.
61. Kiemeney LA, Schoenberg M. Familial transitional cell carcinoma. J Urol 1996; 156: 867-72.
62. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Ka-Prio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
63. Gu J, Liang D, Wang Y, Lu C, Wu X Effects of Nacetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 2005; 581: 97-104.
64. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-59.
65. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol 2007; 18: 1230-42.
66. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000; 10: 115-22.
67. Cui X, Lu X, Hiura M, Omori H, Miyazaki W, Katoh T. Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med 2012 Sep 9.[Epub ahead of print].
68. Kellen E, Hemelt M, Broberg K, Golka K, Kristensen VN, Hung RJ, et al. Pooled analysis and meta-analysis of the glutathione Stransferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol 2007; 165: 1221-30.
69. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front Biosci 2007; 12: 192-213.
70. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 979-87.
71. Chu H, Wang M, Wang M, Gu D, Wu D, Zhang Z, et al. The MPO -463G>A polymorphism and cancer risk: a meta-analysis based on 43 case-control studies. Muta-genesis 2010; 25: 389-95.
72. Christmann M, Tomicic MT, Roos WP, Kaina B. Mech-anisms of human DNA repair: an update. Toxicology 2003; 193: 3-34.
73. Berwick M, Vineis P. Markers of DNA repair, susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92: 874-97.
74. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60: 5612-6.
75. Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312) Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep 2010; 37: 301-9.
76. Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, Kler R. Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol 2012; 31: 199-210.
77. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 125-31.
78. Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Bi-omarkers Prev 2001; 10: 217-22.
79. Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, An-dersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 119-23.
80. Shen H, Xu Y, Qian Y, Yu R, Qin Y, Zhou L, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer 2000; 88: 601-6.
81. Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q, R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis 2008; 23: 523-32.
82. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551: F1-37.
83. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
84. Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009; 30: 487-93.
85. Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009; 17: 1294-303.
86. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
87. Wang M, Wang M, Cheng G, Zhang Z, Fu G, Zhang Z. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat Res 2009; 661: 85-92.
88. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer re-search. Nat Rev Cancer 2010; 10: 389-402.
89. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006; 38: 1452-6.
90. Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, et al. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009; 18: 1183-7.
91. Chu H, Wang M, Shi D, Ma L, Zhang Z, Tong N, et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 2011; 6: e18108.
92. Yue C, Wang M, Ding B, Wang W, Fu S, Zhou D, et al. Polymorphism of the premiR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol Oncol 2011; 122: 33-7.
93. Liu Z, Li G, Wei S, Niu J, El-Naggar AK, Sturgis EM, et al. Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 2010; 116: 4753-60.
94. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Sch-oenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predis-poses to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008; 105: 7269-74.
95. Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, et al. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 2005; 217: 11-6.
96. Yuan L, Gu X, Shao J, Wang M, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol 2010; 29: 611-7.
97. Wang M, Zhu H, Fu G, Wang M, Zhang Z, Lu Q, et al. Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case-control study with meta-analysis. Clin Exp Med 2009; 9: 9-19.
98. Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X. Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol 2009; 19: 540-6.
99. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-7.
100. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
101. Wang M, Wang M, Zhang W, Yuan L, Fu G, Wei Q, et al. Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 2009; 30: 991-6.
102. Lehmann ML, Selinski S, Blaszkewicz M, Orlich M, Ovsiannikov D, Moormann O, et al. Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch Toxicol 2010; 84: 967-78.
103. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metasta-sis Rev 2009; 28: 269-80.
104. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23: 5746-56.
105. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010; 28: 2445-51.
106. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, et al. Highorder interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 2007; 28: 2160-5.
107. Chu H, Ma L, Wang M, Shi D, Qin C, Yuan L, et al. The polymorphisms of IL-4, IL-4R and IL-13 genes and bladder cancer risk in a Chinese population: a case-control study. Mol Biol Rep 2012; 39: 5349-57.
108. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, et al. A genome-wide association study of bladder cancer identifies a new susceptibil-ity locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 2011; 20: 4282-9.